Natera, Inc. (NASDAQ:NTRA) Holdings Lowered by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC lessened its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 42.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 96,996 shares of the medical research company's stock after selling 71,011 shares during the quarter. Segall Bryant & Hamill LLC owned about 0.08% of Natera worth $12,314,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Parnassus Investments LLC increased its position in shares of Natera by 7.6% during the 3rd quarter. Parnassus Investments LLC now owns 9,241 shares of the medical research company's stock valued at $1,173,000 after purchasing an additional 652 shares during the period. Meeder Asset Management Inc. lifted its holdings in shares of Natera by 7,765.9% in the third quarter. Meeder Asset Management Inc. now owns 3,225 shares of the medical research company's stock valued at $409,000 after buying an additional 3,184 shares during the period. First Turn Management LLC bought a new position in Natera during the third quarter valued at about $19,760,000. Swiss National Bank grew its holdings in Natera by 0.9% during the third quarter. Swiss National Bank now owns 227,900 shares of the medical research company's stock worth $28,932,000 after acquiring an additional 2,000 shares during the period. Finally, Thrivent Financial for Lutherans raised its position in Natera by 1.2% in the third quarter. Thrivent Financial for Lutherans now owns 143,903 shares of the medical research company's stock worth $18,269,000 after acquiring an additional 1,685 shares in the last quarter. Institutional investors own 99.90% of the company's stock.

Natera Stock Up 3.6 %

Natera stock opened at $167.88 on Thursday. The company has a market capitalization of $22.16 billion, a P/E ratio of -95.39 and a beta of 1.53. Natera, Inc. has a 1-year low of $53.62 and a 1-year high of $169.71. The firm's fifty day simple moving average is $129.84 and its 200-day simple moving average is $117.00. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million during the quarter, compared to analysts' expectations of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business's quarterly revenue was up 63.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.95) earnings per share. Sell-side analysts forecast that Natera, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Natera

In other news, insider Solomon Moshkevich sold 1,196 shares of the firm's stock in a transaction on Monday, October 28th. The shares were sold at an average price of $118.21, for a total value of $141,379.16. Following the sale, the insider now owns 110,695 shares in the company, valued at approximately $13,085,255.95. This trade represents a 1.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Rowan E. Chapman sold 2,614 shares of the company's stock in a transaction on Friday, September 13th. The shares were sold at an average price of $127.68, for a total transaction of $333,755.52. Following the transaction, the director now owns 7,969 shares of the company's stock, valued at approximately $1,017,481.92. The trade was a 24.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 36,821 shares of company stock worth $4,776,878 over the last 90 days. Insiders own 7.60% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on NTRA. Canaccord Genuity Group raised their price objective on shares of Natera from $150.00 to $165.00 and gave the company a "buy" rating in a research report on Wednesday, November 13th. Leerink Partners raised their target price on shares of Natera from $140.00 to $150.00 and gave the stock an "outperform" rating in a report on Thursday, October 17th. JPMorgan Chase & Co. lifted their price target on shares of Natera from $135.00 to $160.00 and gave the stock an "overweight" rating in a research report on Wednesday, November 13th. Sanford C. Bernstein raised their price objective on Natera from $125.00 to $135.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 30th. Finally, StockNews.com lowered Natera from a "hold" rating to a "sell" rating in a research report on Thursday, November 14th. One analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $140.59.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.